Evolus
Manufacturing · California, United States · 201-500 Employees
View Company Info for Free
Overview
Headquarters
520 Newport Center Dr Ste 1200, Newport ...Phone Number
(949) 284-4555Website
www.evolus.comRevenue
$301.8 MillionStock Symbol
EOLSIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
4
1
1
1
1
1
About Evolus
Evolus is a performance beauty company focused on building an aesthetics portfolio of consumer brands for the cash-pay aesthetics market. Its flagship product, Jeuveau®, is a proprietary neurotoxin indicated for the temporary improvement of moderate to severe glabellar (frown) lines in adults. Through its customer-centric business model and innovative digital platform, the company continues to expand its presence in the aesthetic injectable market. Evolus has also broadened its portfolio with Evolysse®, a collection of advanced injectable hyaluronic acid gels designed to treat facial wrinkles and folds.Explore more
Evolus Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Evolus your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Funding: Get notified immidiatlly once Evolus has new funding data
Evolus, which may be a good buyer, showed buying intent in Masked Content Topic
Product Launch: Get notified when Evolus launches new products
Check if Evolus has recently received funding, and reach out quickly before it becomes old news!
Click to see if Evolus had a recent Job posting/layoffs
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Congratulate Masked Content for being promoted to Masked Content at Evolus
Earning: See what the market has to say on Evolus recently announced quarterly report
Website visits: Recent activity has been detected on your website
Check out if Evolus is spiking on competitors!
Recommended Actions
Find VP level buyers at Evolus
Find 2 more new buyers
Compare Similar Companies to Evolus
Compare insights from companies similar to Evolus, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Evolus is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Evolus is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Evolus.
Evolus financials insights
Gather financial insights about Evolus, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2020
Other Financing Round
$40M
Evolus Tech Stack
A closer look at the technologies used by Evolus
See more technologies
Most Recent Scoops
Project
established a direct presence in the UK approximately four years ago with its Nuceiva toxin brand, which is now approaching double-digit market share, and has since launched its full Estyme filler line in the market.
Project
Evolus has transitioned its operations in Italy and Germany from distributor-led to direct models, while its direct-launch markets in Spain and Australia are each approaching two years in market with growth trajectories steeper than the UK.
Sales
Project
Evolus has announced plans to launch Sculpt, a flagship injectable filler indicated for the mid-face area, pending expected regulatory approval by year-end.
Person-Based
Product Launch, Business Development
Event
Person-Based
Events, Corporate Strategy, Podcast
Evolus News & Media
Evolus Targets Double-Digit Growth, Full-Year Profitability at Needham Healthcare Conference
Evolus (NASDAQ:EOLS) executives told investors at Needham & Company’s 25th Annual Healthcare Conference that the company is pursuing double-digit growth and a transition to full-year profitability as it expands beyond its flagship neurotoxin Jeuveau and scales its newer hyaluronic acid (HA) fillEvolus Sees Toxin Market Stabilizing, Evolysse Gaining Traction, Raises 2028 Revenue Targets at Conference
Evolus (NASDAQ:EOLS) executives said they are seeing signs of stabilization and improvement in the U.S. botulinum toxin market after a period of industry-wide pressure, while describing a slower recovery for dermal fillers amid changing consumer sentiment. Speaking at the Leerink Conference, CEO DavEvolus, Inc. Q4 2025 Earnings Call Summary
Moby summary of Evolus, Inc.'s Q4 2025 earnings callEvolus (EOLS) Q4 2025 Earnings Call Transcript
Nareg Sagherian: Thank you, Operator, and welcome to everyone joining us on today's call to review Evolus, Inc. fourth quarter and full year 2025 financial results. With me today are David Moatazedi, President and Chief Executive Officer, and Tatjana Mitchell, Chief Financial Officer.
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Evolus
Sign Up For FreeTo access detailed company insights
Evolus is a performance beauty company focused on building an aesthetics portfolio of consumer brands for the cash-pay aesthetics market. Its flagship product, Jeuveau®, is a proprietary neurotoxin indicated for the temporary improvement of moderate to severe glabellar (frown) lines in adults. Through its customer-centric business model and innovat... Read More
